9.52
+0.175(+1.87%)
Currency In USD
Address
1500 Broadway
New York City, NY 10036
United States of America
Phone
332 208 6102
Website
Sector
Healthcare
Industry
Biotechnology
Employees
273
First IPO Date
August 26, 2020
| Name | Title | Pay | Year Born |
| David T. Hung | Founder, President, CEO & Chairman | 1.2M | 1958 |
| David C. Hanley | Chief Technical Operations Officer | 586,040 | 1970 |
| Colleen Sjogren | Chief Commercial Officer | 615,841 | 1971 |
| David Liu | Chief Medical Officer | 677,151 | 1970 |
| Gary Hattersley | Chief Scientific Officer | 776,760 | 1967 |
| Stephen Dang | Senior Vice President, General Counsel & Corporate Secretary | 0 | N/A |
| Moses Makunje | Vice President of Finance and Principal Accounting & Financial Officer | 0 | 1978 |
| Philippe Sauvage | Chief Financial Officer & Principal Financial Officer | 0 | 1977 |
| Kerry A. Wentworth | Chief Regulatory Officer | 0 | 1973 |
| Stacy Markel | Chief People Officer | 0 | 1965 |
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.
